Metoclopramida Medinfar (Metoclopramide Hydrochloride Anhydrous)

Metoclopramide works by blocking dopamine D2 receptors in the brain’s chemoreceptor trigger zone and in the gastrointestinal tract. This blockade increases acetylcholine release, which stimulates smooth‑muscle contraction, enhances gastric motility, and reduces the central signaling that triggers nausea and vomiting.

The exact dose of Metoclopramida Medinfar is set by the prescribing clinician. Dosage depends on the specific indication, the patient’s age, renal function, and overall clinical response. The prescriber tailors the regimen to achieve optimal symptom control while minimizing side effects.

Safety data for metoclopramide in pregnancy and lactation are limited. The drug should only be used when the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers should evaluate each case individually and discuss alternatives when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. The sales team will verify trade or institutional credentials, then respond with pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with serotonin‑type antiemetics such as ondansetron, metoclopramide adds a prokinetic effect by stimulating gastric motility. This makes it useful for conditions involving delayed gastric emptying. However, it carries a higher risk of extrapyramidal side effects, so clinicians weigh the benefit‑risk profile based on the patient’s condition.

Metoclopramida Medinfar should be stored at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

The medication is taken orally. Patients should swallow the tablet whole with a glass of water. It may be taken with or without food, although taking it with meals can reduce gastrointestinal discomfort in some individuals.

Serious adverse reactions include extrapyramidal symptoms such as dystonia or akathisia, tardive dyskinesia with long‑term use, and neuroleptic malignant syndrome, a rare but life‑threatening condition. Prompt medical attention is required if any of these symptoms develop.

Metoclopramida Medinfar should be avoided in patients with known hypersensitivity to metoclopramide, in those with gastrointestinal obstruction or perforation, and in individuals with pheochromocytoma, seizure disorders, or severe renal impairment unless specifically advised by a physician.